Drugs / ponsegromab
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials · 1 missed | ||||||
| Phase 1 | NCT07663630 | Jul 2026 → Feb 2028 expected | hypoproteinemia, hypercatabolic, non-small cell lung carcinoma | Pfizer | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05685264 | Jan → Jul 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04803305 | May 2021 → Apr 2022 | breast cancer, colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma +2 | Pfizer | Completed | Missed primary |
| Phase 1 | NCT04299048 | Nov 2020 → Mar 2022 | colorectal cancer, hypoproteinemia, hypercatabolic, malignant pancreatic neoplasm, non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03974776 | Jul 2019 → Jan 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03599063 | Jul 2018 → Sep 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05546476 | Nov 2022 → Mar 2024 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | Pfizer | Completed | Met primary |
| Phase 2 | NCT05492500 | Sep 2022 → Mar 2025 | heart failure | Pfizer | Terminated | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06989437 | Oct 2025 → Jan 2028 expected | hypoproteinemia, hypercatabolic, pancreatic ductal adenocarcinoma | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Pfizer | Results Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia pfizer.com ↗
Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Pfizer | Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ponsegromab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05492500 ↗ |
| Known as | PF-06946860 | “study medicine (Ponsegromab/PF-06946860)” NCT05492500 ↗ |
| Action | Inhibit | “inhibition of GDF-15 with ponsegromab resulted in increased weight gain and overall activity level and reduced cachexia symptoms” PMID 39282907 ↗ Sep 2024 |
| Modality | Monoclonal antibody | “Ponsegromab is a potent and selective humanized monoclonal antibody that inhibits GDF-15-mediated signalling.” PMID 38500292 ↗ Mar 2024 |
| Route | Subcutaneous | “PF-06946860 administered subcutaneously” NCT03599063 ↗ |
| Target | GDF15 | “Ponsegromab is a potent and selective humanized monoclonal antibody that inhibits GDF-15-mediated signalling.” PMID 38500292 ↗ Mar 2024 |